Simulations Plus, Inc. (SLP)

NASDAQHealth CareSoftware - ApplicationSnapshot 2026-10-23

$18.500.00%

Close 2026-10-06 · 1-day change

Investment OutlookAs of Oct 16, 2026

What could strengthen or challenge Simulations Plus, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations

Management figures unavailable.

Current consensus figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EPS of $0.75 to $0.85 in fiscal 2026	Adjusted EPS is expected near $0.80 per share.	Intact	Adjusted EPS falls below $0.75 in fiscal 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 16, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 4 quarters from 2025-Q4 through 2026-Q3. The adjusted EPS guidance was lowered from $1.03-$1.10 to $0.75-$0.85 due to an increased tax rate. Adjusted diluted EPS for the first nine months of 2026 was $0.78, slightly below prior year $0.93, indicating the company is tracking within the revised guidance but with some downward pressure. Delivery assessment Oct 16, 2026
Increase cash from operating activities to at least $6.4M by Q2 2026	A supporting condition in Simulations Plus, Inc.'s published investment case. The stated target is >=6.41 million USD in 2026-Q2.	Improving	Operating cash flow falls below $6.4 million in 2026-Q2	Cash from operations: $10.246M FY2026-Q3; GAAP. Published target: >=6.41 million USD in 2026-Q2. The stored target says 2026-Q2; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Source published Jul 9, 202610,246,000 USD · source valueSource reportLast status assessment Oct 16, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending May 31, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q3. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 quarters including 2025-Q1 and 2026-Q1. Cash from operating activities improved significantly from negative $1.27 million in 2025-Q1 to positive $4.23 million in 2026-Q1, demonstrating progress in operational cash generation. This trajectory indicates delivering on the priority to increase cash flow from operations. Delivery assessment Oct 16, 2026
Revenue reaches $79M to $82M in fiscal 2026	A primary condition in Simulations Plus, Inc.'s published investment case. The stated target is >=79 million USD in fiscal 2026.	Intact	Revenue falls below $79 million in fiscal 2026	Revenue: $21.886M FY2026-Q3; GAAP. Published target: >=79 million USD in fiscal 2026. Target period is not explicitly aligned with this observation. Source published Jul 9, 202621,886,000 USD · source valueSource reportLast status assessment Oct 16, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending May 31, 2026 Source: company_financial_results. Reference: 9deba3ec-024d-498c-af8d-013889204aca. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 quarters from 2025-Q4 through 2026-Q3. Fiscal 2026 revenue guidance of $79M - $82M was consistently reaffirmed. Actual revenue for the first nine months of 2026 grew 5% to $64.6M from $61.7M in the prior year, supporting on-track progress toward the annual guidance range. Delivery assessment Oct 16, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-08-31 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-01	Unavailable	Unavailable	1 / 1
2026-09-02	Unavailable	Unavailable	1 / 1
2026-09-03	Unavailable	Unavailable	1 / 1
2026-09-04	Unavailable	Unavailable	1 / 1
2026-09-05	Unavailable	Unavailable	1 / 1
2026-09-06	Unavailable	Unavailable	1 / 1
2026-09-07	Unavailable	Unavailable	1 / 1
2026-09-08	Unavailable	Unavailable	1 / 1
2026-09-09	Unavailable	Unavailable	1 / 1
2026-09-10	Unavailable	Unavailable	1 / 1
2026-09-11	Unavailable	Unavailable	1 / 1
2026-09-12	Unavailable	Unavailable	1 / 1
2026-09-13	Unavailable	Unavailable	1 / 1
2026-09-14	Unavailable	Unavailable	1 / 1
2026-09-15	Unavailable	Unavailable	1 / 1
2026-09-16	Unavailable	Unavailable	1 / 1
2026-09-17	Unavailable	Unavailable	1 / 1
2026-09-18	Unavailable	Unavailable	1 / 1
2026-09-19	Unavailable	Unavailable	1 / 1
2026-09-20	Unavailable	Unavailable	1 / 1
2026-09-21	Unavailable	Unavailable	1 / 1
2026-09-22	Unavailable	Unavailable	1 / 1
2026-09-23	Unavailable	Unavailable	1 / 1
2026-09-24	Unavailable	Unavailable	1 / 1
2026-09-25	Unavailable	Unavailable	1 / 1
2026-09-26	Unavailable	Unavailable	1 / 1
2026-09-27	Unavailable	Unavailable	1 / 1
2026-09-28	Unavailable	Unavailable	1 / 1
2026-09-29	Unavailable	Unavailable	1 / 1
2026-09-30	Unavailable	Unavailable	1 / 1
2026-10-01	Unavailable	Unavailable	1 / 1
2026-10-02	Unavailable	Unavailable	1 / 1
2026-10-03	Unavailable	Unavailable	1 / 1
2026-10-04	Unavailable	Unavailable	1 / 1
2026-10-05	Unavailable	Unavailable	1 / 1
2026-10-06	Unavailable	Unavailable	1 / 1
2026-10-07	Unavailable	Unavailable	1 / 1
2026-10-08	Unavailable	Unavailable	1 / 1
2026-10-09	Unavailable	Unavailable	1 / 1
2026-10-10	Unavailable	Unavailable	1 / 1
2026-10-11	Unavailable	Unavailable	1 / 1
2026-10-12	Unavailable	Unavailable	1 / 1
2026-10-13	Unavailable	Unavailable	1 / 1
2026-10-14	Unavailable	Unavailable	1 / 1
2026-10-15	Unavailable	Unavailable	1 / 1
2026-10-16	Unavailable	Unavailable	1 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	4
2026-06-01	3	5
2026-07-01	3	5
2026-08-01	0	5
2026-09-01	0	5
2026-10-01	0	5

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 0 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 17–Oct 16 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 17, 2026–Oct 16, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EPS of $0.75 to $0.85 in fiscal 2026Direct metric needs a verified mapping
Increase cash from operating activities to at least $6.4M by Q2 2026Cash from operations: $10.246M
Revenue reaches $79M to $82M in fiscal 2026Revenue: $21.886M

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.1%Typical daily move · historical

Downside history

-45.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Simulations Plus, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a mix of a turnaround and a cyclical play. The current thesis state is intact, driven by recent strong financial performance, but management's volatility adds uncertainty.

What's priced into Simulations Plus, Inc.

The market appears to have priced in a justified valuation, with a low expectations gap. SLP is currently trading at a slight premium compared to its peers, indicating that some positive performance is already expected.

What the fundamentals likely do

Fundamentals are likely to remain stable, supported by on-track revenue guidance and a robust earnings quality. However, the adjusted EPS guidance has been lowered, indicating some downward pressure that investors should monitor.

What Simulations Plus, Inc. hinges on

The long-term thesis hinges on management's ability to complete the merger with Altaris and maintain revenue guidance. Additionally, external factors such as sector performance and economic conditions will be critical, especially if recession fears impact the healthcare sector.